	Cambrex Corporation announced plans for a $5-million expansion of laboratory facilities at its Karlskoga, Sweden site, which includes additional capability and capacity for process development and scale up, handling of potent substances, crystallization studies, and solid phase characterization. Construction on the three story, 600-sq.-m building will begin at the end of second quarter of 2018, with completion due in the second quarter of 2019, the company reported in a May 31, 2018 press announcement.

	The expansion will feature a new technical laboratory with walk-in hoods for laboratory syntheses up to 10 L and will enable handling of potent substances at a large laboratory scale, high-pressure reactions, and parallel synthesis for API route scouting and development.

	The expansion also will feature two analytical development and quality control laboratories and office space for 12 scientists and chemists, bringing the total headcount to 60.

API Synthesis and Manufacturing, Small Molecule

Contract Development Services

Contract Manufacturing, Drug Substance, API

Development

Outsourcing

PharmTech News

Supplier News

Cambrex invests $5 million in new laboratory expansion at its Karlskoga, Sweden facility.